Weekly  versus  three weeks chemotherapy for advanced ovarian cancer: a meta-analysis

Claudia Marchetti; Francesca De Felice; Angela Musella; Innocenza Palaia; Marco Monti; Daniela Musio; Ludovico Muzii; Vincenzo Tombolini; Pierluigi Benedetti Panici

doi:10.18632/oncotarget.11094

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis

Claudia Marchetti _, Francesca De Felice, Angela Musella, Innocenza Palaia, Marco Monti, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini and Pierluigi Benedetti Panici

PDF | HTML | How to cite

Oncotarget. 2016; 7:58709-58715. https://doi.org/10.18632/oncotarget.11094

Metrics: PDF 2407 views | HTML 2367 views | ?

Abstract

Claudia Marchetti1,*, Francesca De Felice2,*, Angela Musella1, Innocenza Palaia1, Marco Monti1, Daniela Musio2, Ludovico Muzii1, Vincenzo Tombolini2, Pierluigi Benedetti Panici1

1 Department of Gynecological and Obstetrical Sciences and Urological Sciences, “Sapienza” University of Rome, Rome, Italy

2 Department of Radiotherapy, Policlinico Umberto I “Sapienza” University of Rome, Rome, Italy

* These authors have equal contribution to this study

Correspondence to:

Francesca De Felice, email:

Keywords: ovarian cancer; dose-dense; carboplatin; paclitaxel; weekly

Received: April 29, 2016 Accepted: June 29, 2016 Published: August 05, 2016

Abstract

Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a meta-analysis to compare the two regimens.

Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity.

Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77-1.16, p=0.06), as well as in term of severe acute toxicity.

Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11094

Publication Alerts

Reviews:

Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis

Abstract